本帖最后由 老马 于 2012-1-13 21:20 编辑 D, V+ T; Y6 X3 U i/ `( j
4 [1 U# F/ S( c% {" F* V爱必妥和阿瓦斯丁的比较3 w- r8 c. T+ k1 B5 K% o
# b/ j c# x& _* U0 ?. Y/ Ihttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
& p9 z8 b+ X) }3 ?& D
! G' j* t. m2 [
( O* O& Q) G. {) Y1 ?" d' ]9 N0 X
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/; }) W1 n' \8 k
==================================================; J$ P5 N( s" D0 D' [
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)4 E* P& d* i, j
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
# e$ ^5 k, v7 _# x1 Z3 o, H# YResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
* `; X9 B2 V; q
|